BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as
well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of …

Eosinophils are innate immune cells that, under certain conditions, can be recruited to the
lungs, where they have an incompletely understood role in health and disease. Eosinophils …

Background Most guidelines recommend either a long-acting beta-agonist (LABA) plus an
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …

Chronic obstructive pulmonary disease (COPD) is a common, complex, and heterogeneous
disorder that is responsible for substantial and growing morbidity, mortality, and health-care …

Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive
biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive …

The publication of the Spanish guideline for chronic obstructive pulmonary disease–COPD–
(GesEPOC) has brought about a change in the approach to the treatment of this disease …

Purpose Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity
and mortality in the United States. Exacerbations—acute worsening of COPD symptoms …

Background Randomized controlled trials (RCTs) indicate that long-acting bronchodilator
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …

Background The current Global initiative for chronic Obstructive Lung Disease (GOLD)
treatment strategy recommends the use of one or more bronchodilators according to the …

Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …